Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$47.86 - $75.05 $1.37 Million - $2.14 Million
-28,562 Reduced 95.12%
1,466 $79,000
Q1 2024

May 14, 2024

SELL
$63.75 - $108.06 $20.4 Million - $34.6 Million
-320,507 Reduced 91.43%
30,028 $2.11 Million
Q4 2023

Feb 13, 2024

BUY
$26.88 - $83.49 $9.16 Million - $28.5 Million
340,827 Added 3510.78%
350,535 $29.3 Million
Q3 2023

Nov 13, 2023

SELL
$29.46 - $36.61 $2.53 Million - $3.14 Million
-85,848 Reduced 89.84%
9,708 $285,000
Q2 2023

Aug 14, 2023

SELL
$32.62 - $40.75 $226,448 - $282,886
-6,942 Reduced 6.77%
95,556 $3.12 Million
Q1 2023

May 15, 2023

BUY
$33.36 - $45.71 $3.42 Million - $4.69 Million
102,498 New
102,498 $3.61 Million
Q4 2021

Feb 01, 2022

SELL
$34.35 - $46.38 $425,046 - $573,906
-12,374 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$18.54 - $35.74 $229,413 - $442,246
12,374 New
12,374 $442,000
Q4 2020

Feb 16, 2021

SELL
$15.26 - $28.61 $209,794 - $393,330
-13,748 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$20.58 - $28.96 $207,672 - $292,235
-10,091 Reduced 42.33%
13,748 $298,000
Q2 2020

Aug 14, 2020

BUY
$11.15 - $24.64 $265,804 - $587,392
23,839 New
23,839 $562,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.69B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.